These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 32919880)

  • 21. COVID-19 convalescent plasma composition and immunological effects in severe patients.
    Acosta-Ampudia Y; Monsalve DM; Rojas M; Rodríguez Y; Gallo JE; Salazar-Uribe JC; Santander MJ; Cala MP; Zapata W; Zapata MI; Manrique R; Pardo-Oviedo JM; Camacho B; Ramírez-Santana C; Anaya JM;
    J Autoimmun; 2021 Mar; 118():102598. PubMed ID: 33524876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial.
    Diago-Sempere E; Bueno JL; Sancho-López A; Rubio EM; Torres F; de Molina RM; Fernández-Cruz A; de Diego IS; Velasco-Iglesias A; Payares-Herrera C; Flecha IC; Avendaño-Solà C; Palomino RD; Ramos-Martínez A; Ruiz-Antorán B
    Trials; 2021 Jan; 22(1):70. PubMed ID: 33472681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early Convalescent Plasma for High-Risk Outpatients with Covid-19.
    Korley FK; Durkalski-Mauldin V; Yeatts SD; Schulman K; Davenport RD; Dumont LJ; El Kassar N; Foster LD; Hah JM; Jaiswal S; Kaplan A; Lowell E; McDyer JF; Quinn J; Triulzi DJ; Van Huysen C; Stevenson VLW; Yadav K; Jones CW; Kea B; Burnett A; Reynolds JC; Greineder CF; Haas NL; Beiser DG; Silbergleit R; Barsan W; Callaway CW;
    N Engl J Med; 2021 Nov; 385(21):1951-1960. PubMed ID: 34407339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants.
    Bellusci L; Golding H; Khurana S
    J Clin Invest; 2023 Apr; 133(8):. PubMed ID: 36821375
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection.
    Gharbharan A; Jordans CCE; GeurtsvanKessel C; den Hollander JG; Karim F; Mollema FPN; Stalenhoef-Schukken JE; Dofferhoff A; Ludwig I; Koster A; Hassing RJ; Bos JC; van Pottelberge GR; Vlasveld IN; Ammerlaan HSM; van Leeuwen-Segarceanu EM; Miedema J; van der Eerden M; Schrama TJ; Papageorgiou G; Te Boekhorst P; Swaneveld FH; Mueller YM; Schreurs MWJ; van Kampen JJA; Rockx B; Okba NMA; Katsikis PD; Koopmans MPG; Haagmans BL; Rokx C; Rijnders BJA
    Nat Commun; 2021 May; 12(1):3189. PubMed ID: 34045486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Convalescent plasma may be a possible treatment for COVID-19: A systematic review.
    Wang Y; Huo P; Dai R; Lv X; Yuan S; Zhang Y; Guo Y; Li R; Yu Q; Zhu K
    Int Immunopharmacol; 2021 Feb; 91():107262. PubMed ID: 33338863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
    Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ
    Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma therapy: a passive resistance against the deadliest.
    Hansda A; Biswas D; Bhatta A; Chakravorty N; Mukherjee G
    Hum Vaccin Immunother; 2022 Apr; 18(2):2006026. PubMed ID: 34886756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma.
    Natarajan H; Crowley AR; Butler SE; Xu S; Weiner JA; Bloch EM; Littlefield K; Wieland-Alter W; Connor RI; Wright PF; Benner SE; Bonny TS; Laeyendecker O; Sullivan D; Shoham S; Quinn TC; Larman HB; Casadevall A; Pekosz A; Redd AD; Tobian AAR; Ackerman ME
    mBio; 2021 Apr; 12(2):. PubMed ID: 33879585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma.
    Maeda K; Higashi-Kuwata N; Kinoshita N; Kutsuna S; Tsuchiya K; Hattori SI; Matsuda K; Takamatsu Y; Gatanaga H; Oka S; Sugiyama H; Ohmagari N; Mitsuya H
    Sci Rep; 2021 Mar; 11(1):5563. PubMed ID: 33692457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
    Rnjak D; Ravlić S; Šola AM; Halassy B; Šemnički J; Šuperba M; Hećimović A; Kurolt IC; Kurtović T; Mačak Šafranko Ž; Polančec D; Bendelja K; Mušlin T; Jukić I; Vuk T; Zenić L; Artuković M
    Transfus Clin Biol; 2021 Aug; 28(3):264-270. PubMed ID: 33901641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 neutralizing capacity among blood donors without prior COVID-19 symptomatic history vs. blood donors with prior COVID-19 symptomatic history: A comparative study.
    Ravula U; Chunchu SR; Mooli S; Naik R; Sarangapati PRR
    Transfus Clin Biol; 2022 May; 29(2):107-111. PubMed ID: 35167958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy.
    Devarasetti PK; Rajasekhar L; Baisya R; Sreejitha KS; Vardhan YK
    Immunol Res; 2021 Feb; 69(1):18-25. PubMed ID: 33492637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune reactivity during COVID-19: Implications for treatment.
    Napoli C; Benincasa G; Criscuolo C; Faenza M; Liberato C; Rusciano M
    Immunol Lett; 2021 Mar; 231():28-34. PubMed ID: 33421440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients.
    Thümmler L; Lindemann M; Horn PA; Lenz V; Konik M; Gäckler A; Boss K; Theodoropoulos F; Besa V; Taube C; Brenner T; Witzke O; Krawczyk A; Rohn H
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune-Based Therapy for COVID-19.
    Esmaeilzadeh A; Jafari D; Tahmasebi S; Elahi R; Khosh E
    Adv Exp Med Biol; 2021; 1318():449-468. PubMed ID: 33973194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.